Everything below concerns pentadecapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
Yohimbine selectively blocks the pre-synaptic α2-adrenergic receptors. Blockade of post-synaptic α2-adrenergic receptors causes only minor corpus cavernosum smooth muscle relaxation, due to the fact that the majority of adrenoceptors in the corpus cavernosum are of the α1 type. Blockade of pre-synaptic α2-adrenergic receptors facilitates the release of several neurotransmitters in the central and peripheral nervous system—thus in the corpus cavernosum—such as nitric oxide and norepinephrine. Whereas nitric oxide released in the corpus cavernosum is the major vasodilator contributing to the erectile process, norepinephrine is the major vasoconstrictor through stimulation of α1-adrenergic receptors on the corpus cavernosum smooth muscle. Under physiologic conditions, however, nitric oxide attenuates norepinephrine vasoconstriction. Yohimbine binds to the a2 adrenergic receptor at a ratio of 40:1 and is the only a2 adrenergic receptor antagonist with no imidazoline receptor activity.
Kevin Darnell Hart (born July 6, 1979) is an American comedian and actor. After winning several stand-up comedy competitions, Hart had his first breakthrough when Judd Apatow cast him in a recurring role on the TV series Undeclared (2001). Hart's comedic reputation continued to grow with the release of his first stand-up album I'm a Grown Little Man (2009). He has since released four more comedy albums: Seriously Funny (2010), Laugh at My Pain (2011), Let Me Explain (2013), and What Now? (2016). As an actor, Hart has had roles in films such as Paper Soldiers (2002), Scary Movie 3 (2003), Soul Plane (2004), In the Mix (2005), Little Fockers (2010), Think Like a Man (2012), Grudge Match (2013), Ride Along (2014), About Last Night (2014), Get Hard (2015), Central Intelligence (2016), The Secret Life of Pets film franchise (2016–2019), Ride Along 2 (2016), Captain Underpants: The First Epic Movie (2017), the Jumanji film franchise (2017–present), and Night School (2018). He also created and starred as a fictionalized version of himself in Real Husbands of Hollywood (2013–2016). In 2017, he launched the Laugh Out Loud Network, a subscription video streaming service in partnership with Lionsgate. Hart has received numerous accolades including the Mark Twain Prize for American Humor in 2024, and nominations for two Grammy Awards and four Primetime Emmy Awards. In 2015, Time magazine named him on its annual list of the 100 most influential people in the world.
=== Mechanotransductive === Additionally, YAP is regulated by mechanical cues such as extracellular matrix (ECM) rigidity, strain, shear stress, or adhesive area, processes that are reliant on cytoskeletal integrity. These mechanically induced localization phenomena are thought to be the result of nuclear flattening induced pore size change, mechanosensitive nuclear membrane ion channels, mechanical protein stability, or a variety of other factors. These mechanical factors have also been linked to certain cancer cells via nuclear softening and higher ECM stiffnesses. Under this framework, the nuclear softening phenotype of cancer cells would promote nuclear flattening in response to a force, causing YAP localization, which could explain its over-expression and promoted proliferation in oncogenic cells. Additionally, the higher ECM stiffness phenotype commonly seen in tumors due to enhanced integrin signaling could flatten the cell and nucleus, once again causing higher YAP nuclear localization. Likewise, the opposite effect of nuclear stiffening as a result of a variety of stimuli such as an over-expression of lamin A, has been shown to decrease nuclear YAP localization.
=== Angiogenesis for cardiovascular disease === Angiogenesis represents an excellent therapeutic target for the treatment of cardiovascular disease. It is a potent, physiological process that underlies the natural manner in which our bodies respond to a diminution of blood supply to vital organs, namely neoangiogenesis: the production of new collateral vessels to overcome the ischemic insult. A large number of preclinical studies have been performed with protein-, gene- and cell-based therapies in animal models of cardiac ischemia, as well as models of peripheral artery disease. Reproducible and credible successes in these early animal studies led to high enthusiasm that this new therapeutic approach could be rapidly translated to a clinical benefit for millions of patients in the Western world with these disorders. A decade of clinical testing both gene- and protein-based therapies designed to stimulate angiogenesis in underperfused tissues and organs, however, has led from one disappointment to another. Although all of these preclinical readouts, which offered great promise for the transition of angiogenesis therapy from animals to humans, were in one fashion or another, incorporated into early stage clinical trials, the FDA has, to date (2007), insisted that the primary endpoint for approval of an angiogenic agent must be an improvement in exercise performance of treated patients.
=== NAD+ pptimization === 1-MNA is an inhibitor of nicotinamide N-methyltransferase (NNMT). By inhibiting NNMT activity, it regulates NAD+ biosynthesis via the nicotinamide salvage pathway, the primary route for NAD+ synthesis in mammals. By participating in this pathway, 1-MNA optimizes NAD+ levels.
Sources: en.wikipedia.org
== External links == Peripheral membrane proteins in OPM database DOLOP Genomics-oriented database of bacterial lipoproteins Peptaibol database Archived 2011-01-27 at the Wayback Machine Antimicrobial Peptide Database Archived 2011-07-20 at the Wayback Machine
The pelycosaurs are synapsids (more closely related to mammals) while the ctenosauriscids are archosaurs (closely related to crocodilians, pterosaurs and dinosaurs). Also, the spinosaurids had sail-like fins on their backs, when they were not closely related to either. Also, Acrocanthosaurus and Ouranosaurus, which are not closely related to either pelycosaurs, ctenosauriscids or spinosaurids, also had similar, but thicker, spines on their vertebrae. Noasaurus, Baryonyx, and Megaraptor, all unrelated, all had an enlarged hand claw that were originally thought to be placed on the foot, as in dromaeosaurs. A similarly modified claw (or in this case, finger) is on the hand of Iguanodon. The ornithopods had feet and beaks that resembled that of birds, but are only distantly related. Three groups of dinosaurs, the Tyrannosauridae, Ornithomimosauria, and the Troodontidae, all evolved an arctometatarsus, independently. Some placodonts (like Cyamodus, Psephoderma, Henodus and especially Placochelys) bear striking resemblance to sea turtles (and turtles in general) in terms of size, shell, beak, mostly toothless jaws, paddle-shaped limbs and possibly other adaptations for aquatic lifestyle.
SCID mice were and still are used in disease, vaccine, and transplant research, especially as animal models for testing the safety of new vaccines or therapeutic agents in people with weakened immune system. SCID mice also serve as a useful animal model in the study of the human immune system and its interactions with disease, infections, and cancer. For example, normal strains of mice can be lethally irradiated, killing all rapidly dividing cells. These mice then receive bone marrow transplantation from SCID donors, allowing engraftment of human peripheral blood mononuclear cells (PBMC) to occur. This method can be used to study whether T cell-lacking mice can perform hematopoiesis after receiving human PBMC. A recessive gene, with clinical signs similar to the human condition, affects the Arabian horse. The condition remains a fatal disease, as the horse inevitably succumbs to an opportunistic infection within the first four to six months of life. However, carriers, who themselves are not affected by the disease, can be detected with a DNA test. Therefore, careful breeding practices can avoid the risk of an affected foal being produced. Another animal with well-characterized SCID pathology is the dog. There are two known forms: an X-linked SCID in Basset Hounds that has similar ontology to X-SCID in humans and an autosomal recessive form seen in one line of Jack Russell Terriers that is similar to SCID in Arabian horses and mice.
=== In adult stem cells === Ferroptosis has emerged as a significant regulator of adult stem cell maintenance and tissue regeneration. In human hematopoietic stem cells (HSCs), a naturally low rate of protein synthesis creates a selective vulnerability to ferroptosis; key protective factors such as GPX4, SLC7A11, and ferritin are insufficiently produced, and blocking ferroptosis fully rescues HSC maintenance even without restoring protein synthesis rates. In muscle stem cells (MuSCs), age-related chronic inflammation drives an epigenetic erosion of the histone mark H4K20me1 by downregulating its methyltransferase Kmt5a. This leads to the transcriptional silencing of anti-ferroptotic genes, including Gpx4, Ftl1, and Gclc, resulting in intracellular iron accumulation, lipid peroxidation, and ferroptotic death of MuSCs. The resulting depletion of the MuSC pool impairs muscle regeneration and contributes to age-related sarcopenia. Long-term pharmacological inhibition of systemic inflammation or restoration of the Kmt5a–H4K20me1 axis has been shown to prevent MuSC ferroptosis and improve regenerative capacity in aged muscle tissue.
=== Comparative effectiveness === A major systematic review and network meta-analysis of medications for the treatment of insomnia was published in 2022. It found a widely varying range of effect sizes (standardized mean difference or SMD) in terms of clinical effectiveness for insomnia. The assessed medications and their effect sizes included benzodiazepines (e.g., temazepam, triazolam, many others) (SMDs 0.58 to 0.83), Z-drugs (eszopiclone, zaleplon, zolpidem, zopiclone) (SMDs 0.03 to 0.63), sedative antidepressants and antihistamines (doxepin, doxylamine, trazodone, trimipramine) (SMDs 0.30 to 0.55), the antipsychotic quetiapine (SMD 0.07), orexin receptor antagonists (daridorexant, lemborexant, seltorexant, suvorexant) (SMDs 0.23 to 0.44), and melatonin receptor agonists (melatonin, ramelteon) (SMDs 0.00 to 0.13). The certainty of evidence varied and ranged from high to very low depending on the medication. Certain medications often used as hypnotics, including the antihistamines diphenhydramine, hydroxyzine, and promethazine and the antidepressants amitriptyline and mirtazapine among others, were not included in analyses due to insufficient data.
Sources: en.wikipedia.org
== Population pharmacokinetics == Population pharmacokinetics (popPK) is the study of the sources and correlates of variability in drug concentrations among individuals who are the target patient population receiving clinically relevant doses of a drug of interest. Certain patient demographic, pathophysiological, and therapeutical features, such as body weight, excretory and metabolic functions, and the presence of other therapies, can regularly alter dose-concentration relationships and can explain variability in exposures. For example, steady-state concentrations of drugs eliminated mostly by the kidney are usually greater in patients with kidney failure than they are in patients with normal kidney function receiving the same drug dosage. Population pharmacokinetics seeks to identify the measurable pathophysiologic factors and explain sources of variability that cause changes in the dose-concentration relationship and the extent of these changes so that, if such changes are associated with clinically relevant and significant shifts in exposures that impact the therapeutic index, dosage can be appropriately modified. Additionally, an advantage of population pharmacokinetic modelling is its ability to analyze sparse data sets (sometimes only one concentration measurement per patient is available).
tmax: Time to achieve a maximum plasma concentration t1/2: Biological half-life Atomoxetine The pharmacokinetics of atomoxetine are similar in children, teenagers and adults. Pharmacokinetics of atomoxetine has not been studied in children younger than 6 years old. Pharmacokinetic studies have shown that atomoxetine capsules and oral solutions are equivalent. Atomoxetine is very water soluble so it absorbed rapidly and completely after oral administration. Atomoxetine reaches Cmax 1 to 2 hours after administration. The bioavailability of atomoxetine after oral administration is 63-94%, it is dependent on individual differences in the first-pass metabolism. Atomoxetine is widely distributed and is highly (98%) bound to plasma proteins, mainly albumin. The volume of distribution for atomoxetine is 0.85 L/kg, with limited partitioning into red blood cells. Atomoxetine is mainly metabolized by the cytochrome P4502D6 (CYP2D6) enzyme system. The main metabolite formed is 4-hydroxyatomoxetine, which glucuronate rapidly. 4-hydroxyatomoxetine is equivalent to atomoxetine but is much lower in plasma. The mean elimination half-life of atomoxetine after oral administration is 3.6 hours in individuals in extensive metabolism and 21 hours in those with a slow metabolism. Atomoxetine is excreted mainly as 4-hydroxyatomoxetin-O-glucoronide with urine. Reboxetine If 4 mg of reboxetine is taken orally by a healthy adult, the peak levels can be about 130 ng/mL and are achieved within 2 hours after administration.
Artistic Achievement – Hellblade: Senua's Sacrifice Audio Achievement – Hellblade: Senua's Sacrifice Best Game – What Remains of Edith Finch British Game – Hellblade: Senua's Sacrifice Debut Game – Gorogoa Evolving Game – Overwatch Family – Super Mario Odyssey Game Beyond Entertainment – Hellblade: Senua's Sacrifice Game Design – Super Mario Odyssey Game Innovation – The Legend of Zelda: Breath of the Wild Mobile Game – Golf Clash Multiplayer – Divinity: Original Sin II Music – Cuphead Narrative – Night in the Woods Original Property – Horizon Zero Dawn Performer – Melina Juergens (as Senua, Hellblade: Senua's Sacrifice) Special Award: Nolan North
== Dried blood spot testing for HIV infection == The technology aims to improve diagnostic services to HIV-infected infants and patients, starting treatment, and suppressing the virus from replicating. It is ideal in resource-poor settings due to the samples' longer lifespan with reduced need for refrigeration and the less invasive nature of the test compared with other methods. Unlike ELISA testing for HIV-antibodies in the blood, which may be transmitted to infants in pregnancy independently of the virus itself, dried blood spot testing can be used to detect the genetic material of the actual virus, thereby avoiding the likelihood of a false positive result. DBS specimens also pose less of a biohazard risk to handlers, and are easier to transport or store than liquid blood specimens. Results from DBS correlate with traditional plasma testing, the standard sample. This technology is available in countries with high HIV prevalence, made possible by collaborating with different health organisations and national governments.
Fatty acids are also components of the phospholipids that make up the bulk of the lipid bilayers of all cellular membranes. In plants, de novo fatty acid synthesis occurs in the plastids. Many seeds accumulate large reservoirs of seed oils to support germination and early growth of the seedling before it is a net photosynthetic organism. Mitochondrial fatty acid synthesis (mtFAS): Mitochondrial acetyl-CoA is converted to malonyl-CoA by the mitochondrial isoform of acetyl-CoA carboxylase 1 (mtACC1), in tandem with acyl-CoA synthetase family member 3 (ACSF3), which additionally generates malonyl-CoA from malonate, together providing the extender units for mitochondrial fatty acid synthesis (mtFAS). In response to mitochondrial acetyl-CoA availability, mtFAS builds acyl chains on the matrix-soluble acyl carrier protein (holo-ACP), producing acyl-ACP species with varying chain lengths. These acyl-ACP species are required for the biosynthesis of lipoic acid—a cofactor of key mitochondrial enzyme complexes such as the pyruvate dehydrogenase complex (PDC), the 2-oxoglutarate dehydrogenase complex (OGDC), the 2-oxoadipate dehydrogenase complex (OADHC), the branched-chain α-keto acid dehydrogenase complex (BCKDHC), and the glycine cleavage system—as well as for the allosteric activation of the LYRM protein network. Members of this network regulate iron–sulfur cluster biogenesis, assembly of the electron transport chain complexes, and mitochondrial translation, which remains active even under conditions of limited acetyl-CoA availability.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.